www.lilly.co.uk

Eli Lilly and Company Limited
Lilly House
Priestley Road
Basingstoke
Hampshire
RG24 9NL
England

Phone +44 (0) 1256 315000

Direct Healthcare Professional Communication

28 January 2019

LARTRUVO®▼(olaratumab): no new patients to be initiated after study shows no clinical benefit

Dear Healthcare Professional,

Eli Lilly and Company in agreement with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) would like to inform you of the following:

Summary

- The global phase 3 study (ANNOUNCE) of olaratumab in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS) did not show the clinical benefit (survival and progression-free survival) as compared with doxorubicin, a standard of survival care treatment.
- No new patients should be prescribed olaratumab.
- While further assessment of the study results is ongoing, physicians may consider continuing olaratumab treatment in patients who experience clinical benefit.
- No new safety concerns were identified during the study and the safety profile was comparable between treatment arms.

Background information

Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.

Olaratumab had previously shown an overall survival benefit in soft tissue sarcoma in a US-only randomized phase 2 trial, which led to the conditional marketing authorisation by the European Medicines Agency. Continued approval is contingent upon verification of clinical benefit in the confirmatory trial ANNOUNCE.

The ANNOUNCE study did not confirm the clinical benefit of olaratumab in combination with doxorubicin as compared to doxorubicin, a standard of care treatment. Specifically, the study did not meet the primary endpoints to prolong survival in the overall population (HR: 1.05; Median 20.4 vs. 19.7 months for olaratumab + doxorubicin and doxorubicin, respectively) or in the leiomyosarcoma (LMS) sub-population (HR: 0.95; Median 21.6 vs. 21.9 months for olaratumab +

doxorubicin and doxorubicin, respectively). There was no clinical benefit in key secondary efficacy endpoints (progression-free survival in the overall population: HR 1.231 p-value 0.042; median 5.42 months vs. 6.77 months for olaratumab + doxorubicin and doxorubicin, respectively). No new safety concerns were identified and the safety profile was comparable between treatment arms.

Lilly is reviewing the full results of the ANNOUNCE study and is working with global regulators to determine the appropriate next steps for olaratumab.

While these discussions are ongoing, patients who are currently receiving olaratumab may, in consultation with their physician, continue their course of therapy if receiving clinical benefit.

However, the results of the ANNOUNCE study do not support new patients with soft tissue sarcoma starting olaratumab.

Call for reporting

Lartruvo▼ is subject to additional monitoring. This will allow quick identification of new safety information.

Please report ANY suspected adverse drug reactions (ADRs) to new drugs and vaccines identified by the black triangle▼ to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report ADRs online via the Yellow Cards website - https://yellowcard.mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store.

Alternatively, prepaid Yellow Cards for reporting are available:

- by writing to FREEPOST YELLOW CARD (no other address details necessary)
- by emailing yellowcard@mhra.gov.uk
- at the back of the British National Formulary (BNF)
- by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789 or
- by downloading and printing a form from the Yellow Card website (see link above)

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name.

Company Contact Point

Please do not hesitate to contact Eli Lilly and Company Limited at: +44 1256 315000 for further clarification of your questions.

Yours sincerely,

Dr. Arash Tahbaz MD

Senior Medical Director

Eli Lilly UK, Ireland and Nordics